Rituximab, by depleting CD19+ and CD20+ B cells, has been utilized to treat B‐cell lymphomas since 1997 and is also effective for treating rheumatoid arthritis and membranous nephropathy [17–19]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.